(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.


Figure 3


Fig. 3. In vivo CPA treatment. (A) Levels of fRLX mRNA determined by RT-PCR on initial control (lane 3), 15 days control (lane 4) and 15 days CPA-treated (lane 5) frog testis. Lane 1: molecular mass marker VIX (Roche Diagnostic); lane 2: control PCR. (B) fP1 mRNA levels used as control. (C,D) In situ hybridization of fRLX antisense mRNA on the control (C) and in the CPA-treated frog testis (D).